AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now

Unveiled Friday morning, AbbVie’s Q3 results and earnings call show a company bracing for what could be steep Humira losses with the coming of biosimilar competitors early next year, even as the rest of its immunology franchise outpaces initial expectations.